Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:57 pm Sale | 13G | VYNE THERAPEUTICS INC PAR$ VYNE | CITADEL ADVISORS LLC | 1,181,144 8.5% | -23 (-0.00%) | View |
| 2024-02-02 09:42 am Sale | 13G | VYNE THERAPEUTICS INC PAR$ VYNE | Soleus Capital Master Fund L.P. | 703,868 5% | -187,000 (-20.99%) | View |
| 2023-11-13 4:41 pm Purchase | 13G | VYNE THERAPEUTICS INC PAR$ VYNE | CITADEL ADVISORS LLC | 1,181,167 8.5% | 1,181,167 (New Position) | View |
| 2023-11-13 4:10 pm Purchase | 13G | VYNE THERAPEUTICS INC PAR$ VYNE | EVENTIDE ASSET MANAGEMENT LLC | 1,394,336 9.99% | 1,394,336 (New Position) | View |
| 2023-11-13 4:03 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | Cormorant Asset Management LP | 1,394,336 9.99% | 1,394,336 (New Position) | View |
| 2023-11-13 08:24 am Purchase | 13D | VYNE THERAPEUTICS INC VYNE | AI Biotechnology LLC | 3,201,980 19.99% | 3,201,980 (New Position) | View |
| 2023-11-02 4:15 pm Purchase | 13G | VYNE THERAPEUTICS INC PAR$ VYNE | Soleus Capital Master Fund L.P. | 890,868 6.4% | 890,868 (New Position) | View |
| 2022-02-14 7:33 pm Sale | 13G | VYNE THERAPEUTICS INC VYNE | PERCEPTIVE ADVISORS LLC | 2,425,604 4.5% | -2,562,283 (-51.37%) | View |
| 2021-08-25 5:04 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | PERCEPTIVE ADVISORS LLC | 4,987,887 9.6% | 4,987,887 (New Position) | View |
| 2021-07-09 6:05 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | BlackRock Inc. BLK | 1,037,677 2% | 1,037,677 (New Position) | View |
| 2021-02-16 4:13 pm Unchanged | 13G | VYNE THERAPEUTICS INC VYNE | GREAT POINT PARTNERS LLC | 0 0% | 0 (Unchanged) | View |
| 2021-02-16 3:39 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | PERCEPTIVE ADVISORS LLC | 27,095,819 14.3% | 27,095,819 (New Position) | View |
| 2021-02-16 3:28 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | Point72 Asset Management L.P. | 26,040 0.1% | 26,040 (New Position) | View |
| 2021-02-16 2:41 pm Sale | 13G | MENLO THERAPEUTICS INC MNLO | FIRST MANHATTAN CO. LLC. | 21,319 0.01% | -2,146,694 (-99.02%) | View |
| 2021-02-11 1:56 pm Sale | 13G | MENLO THERAPEUTICS INC MNLO | JANUS HENDERSON GROUP PLC JHG | 0 0% | -1,281,133 (Position Closed) | View |
| 2021-02-02 3:13 pm Purchase | 13G | VYNE THERAPEUTICS INC VYNE | BlackRock Inc. BLK | 11,988,767 7.1% | 11,988,767 (New Position) | View |
| 2020-06-11 5:10 pm Purchase | 13G | MENLO THERAPEUTICS INC MNLO | PERCEPTIVE ADVISORS LLC | 22,876,410 14% | 22,876,410 (New Position) | View |
| 2020-06-11 5:09 pm Sale | 13G | MENLO THERAPEUTICS INC MNLO | Vivo Capital VIII LLC | 3,643,824 2.2% | -367,412 (-9.16%) | View |
| 2020-04-16 12:47 pm Sale | 13D | MENLO THERAPEUTICS INC MNLO | venBio Global Strategic Fund II L.P. | 0 0% | -1,461,552 (Position Closed) | View |
| 2020-02-14 4:20 pm Sale | 13G | MENLO THERAPEUTICS INC MNLO | GREAT POINT PARTNERS LLC | 1,652,013 6.81% | -552,394 (-25.06%) | View |